Search results for "acids"

showing 10 items of 3520 documents

Dietary intake and major food sources of polyphenols in a Spanish population at high cardiovascular risk: the PREDIMED study.

2013

[Background and aims]: Epidemiological data have shown an inverse association between the consumption of polyphenol-rich foods and the risk of cardiovascular disease or overall mortality. A comprehensive estimation of individual polyphenol intake in nutritional cohorts is needed to gain a better understanding of this association. The aim of this study was to estimate the quantitative intake of polyphenols and the major dietary sources in the PREDIMED (PREvención con DIeta MEDiterránea) cohort using individual food consumption records. [Methods and results]: The PREDIMED study is a large, parallel-group, multicentre, randomised, controlled 5-year feeding trial aimed at assessing the effects …

MaleRiskAgingmedicine.medical_specialtyCoumaric AcidsConsumptionMediterranean dietEndocrinology Diabetes and MetabolismQuinic AcidMedicine (miscellaneous)Diet MediterraneanCoffeelaw.inventionCohort StudiesPhenolsRandomized controlled trialFunctional FoodlawOleaMediterranean dietEpidemiologyHumansPlant OilsMedicineFood scienceAgedAged 80 and overFlavonoidsNutrition and Dieteticsbusiness.industryPolyphenolsPhenol-Explorer databasefood and beveragesPREDIMED studyMiddle AgedPredimedSpanish populationClinical trialCardiovascular DiseasesSpainPolyphenolFruitCohortFemaleChlorogenic AcidCardiology and Cardiovascular MedicinebusinessOlive oil
researchProduct

Consumption of Fish and ω-3 Fatty Acids and Cancer Risk: An Umbrella Review of Meta-Analyses of Observational Studies

2020

Multiple studies have suggested that ω-3 fatty acid intake may have a protective effect on cancer risk; however, its true association with cancer risk remains controversial. We performed an umbrella review of meta-analyses to summarize and evaluate the evidence for the association between ω-3 fatty acid intake and cancer outcomes. We searched PubMed, Embase, and the Cochrane Database of Systematic Reviews from inception to December 1, 2018. We included meta-analyses of observational studies that examined associations between intake of fish or ω-3 fatty acid and cancer risk (gastrointestinal, liver, breast, gynecologic, prostate, brain, lung, and skin) and determined the level of evidence of…

MaleRiskOncologymedicine.medical_specialty[SDV]Life Sciences [q-bio]BFMedicine (miscellaneous)ReviewCohort Studies03 medical and health sciencesProstate cancer0302 clinical medicineBreast cancerω-3 fatty acidMeta-Analysis as TopicNeoplasmsInternal medicineFatty Acids Omega-3medicineAnimalsHumanscancer030212 general & internal medicineω-3 fatty acid fish cancer umbrella review meta-analysischemistry.chemical_classificationfishNutrition and Dieteticsumbrella reviewbusiness.industryEndometrial cancerFishesFatty acidCancermedicine.diseaseR13. Good healthmeta-analysisObservational Studies as TopicchemistryCase-Control Studies030220 oncology & carcinogenesisMeta-analysisFemaleSkin cancerbusinessLiver cancerFood Science
researchProduct

Statins, Fracture Risk, and Bone Remodeling: What Is True?

2006

Besides the action on plasma lipid levels, statins show a series of ancillary effects defined as all of their vascular and nonvascular effects independent from the cholesterol reduction. It has been recently hypothesized that one of these ancillary effects could be the improvement of bone health, due to the interference with bone metabolism. This may potentially represent the rationale for statins' use in the treatment of osteoporosis, the most common disease of the bone. Both experimental observations and clinical studies on this topic generated a number of conflicting results; however, the largest randomized clinical trials, the Scandinavian Simvastatin Survival Study (4S), Long Term Inte…

MaleRiskSimvastatinmedicine.medical_specialtyOsteoporosisMyocardial IschemiaBioinformaticsBone remodelinglaw.inventionFractures Bonechemistry.chemical_compoundRandomized controlled trialRisk FactorslawHumansMedicineLongitudinal StudiesRisk factorPravastatinRandomized Controlled Trials as Topicbusiness.industryCholesterolOsteoporosiStatinnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseSurgerychemistrySimvastatinOsteoporosisFemalelipids (amino acids peptides and proteins)Bone RemodelingTherapyHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessFracturesHeart Protection StudyPravastatinmedicine.drugThe American Journal of the Medical Sciences
researchProduct

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

2017

Item does not contain fulltext BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent re…

MaleSTATIN THERAPYAnticholesteremic Agents/adverse effectsAntibodieVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Injections Subcutaneous/adverse effects030204 cardiovascular system & hematologyBococizumablaw.inventionPCSK90302 clinical medicineRandomized controlled triallawRisk FactorsGENETIC-VARIANTSCardiovascular DiseaseMonoclonalAnticholesteremic Agent030212 general & internal medicineMyocardial infarctionTreatment FailureHumanizedProprotein Convertase 9/antagonists & inhibitorsMedicine(all)Antibodies; Antibodies Monoclonal Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Injections Subcutaneous; Lipids; Male; Middle Aged; Proprotein Convertase 9; Risk Factors; Treatment Failure; Medicine (all)Anticholesteremic AgentsMedicine (all)PCSK9 InhibitorsAntibodies; antibodies monoclonal humanized; anticholesteremic agents; cardiovascular diseases; cholesterol LDL; double-blind method; female; follow-up studies; humans; hypercholesterolemia; injections subcutaneous; lipids; male; middle aged; proprotein convertase 9; risk factors; treatment failure; medicine (all)Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16]General MedicineLipidMiddle AgedLipids3. Good healthLDL/bloodMulticenter StudyCholesterolTRIALSCholesterol LDL/bloodCardiovascular DiseasesAntibodies Monoclonal Humanized/adverse effectsanticholesteremic agentsRandomized Controlled Trialsubcutaneouslipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Cardiovascular Diseases/prevention & controlREDUCING LIPIDSHumanmedicine.medical_specialtyanimal structuresInjections SubcutaneousHypercholesterolemiaHypercholesterolemia/drug therapyPlaceboAntibodies Monoclonal HumanizedInjections SubcutaneouAntibodiesLDLInjectionsFollow-Up StudielipidsEVENTS03 medical and health sciencesantibodies monoclonal humanizedDouble-Blind MethodInternal medicinemedicineJournal ArticleHumansComparative StudyMETAANALYSISAlirocumabbusiness.industryUnstable anginaLipids/bloodPCSK9Risk FactorfungiAntibodies/bloodCholesterol LDLta3121medicine.diseaseSurgerycardiovascular diseasesEvolocumabREDUCTIONHumanized/adverse effectsSubcutaneous/adverse effectsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct

Hope for Disease-Modifying Treatment of Systemic Sclerosis/Scleroderma

2014

Systemic sclerosis (SSc), or scleroderma, similar to many fibrotic disorders, lacks effective therapies. Current trials focus on anti-inflammatory drugs or targeted approaches aimed at one of the many receptor mechanisms initiating fibrosis. In light of evidence that a myocardin-related transcription factor (MRTF)–and serum response factor (SRF)–regulated gene transcriptional program induced by Rho GTPases is essential for myofibroblast activation, we explored the hypothesis that inhibitors of this pathway may represent novel antifibrotics. MRTF/SRF-regulated genes show spontaneously increased expression in primary dermal fibroblasts from patients with diffuse cutaneous SSc. A novel small-m…

MaleSerum Response Factormedicine.medical_specialtyOncogene Proteins FusionTranscription GeneticNipecotic AcidsDiseaseSclerodermaDrug Discovery and Translational MedicineInternal medicinemedicineAnimalsHumansMyofibroblastsskin and connective tissue diseasesPharmacologyScleroderma Systemicintegumentary systembusiness.industrymedicine.diseaseConnective tissue diseaseDermatologyRheumatologyDNA-Binding Proteinsstomatognathic diseasesMolecular MedicineFemalebusinessJournal of Pharmacology and Experimental Therapeutics
researchProduct

Inhibition of phospholipase A2 activities and some inflammatory responses by the marine product ircinin

1996

The marine product ircinin has been tested for its effects on secretory and cytosolic phospholipase A2 (PLA2) activities in vitro as well as for inhibition of cellular functions in human neutrophils and inflammatory responses in mice. Ircinin inhibited Naja naja venom, human synovial recombinant, bee venom and zymosan-injected rat air pouch PLA2 with IC50 values in the microM range, similar to those of the known inhibitor scalaradial. On the other hand, ircinin was less active on cytosolic PLA2 from human monocytes and decreased potently the release of LTB4 in human neutrophils. This marine product affected weakly human neutrophil functions like superoxide generation and degranulation. In t…

MaleSesterterpenesNeutrophilsAnti-Inflammatory AgentsInflammationPharmacologyPhospholipases AMicechemistry.chemical_compoundPhospholipase A2SuperoxidesIn vivomedicineAnimalsEdemaHumansPharmacologyAnalysis of VarianceDose-Response Relationship DrugbiologyTerpenesSuperoxideDegranulationGeneral MedicineLeukotriene A4In vitroPoriferaRatsPhospholipases A2CytosolchemistryBiochemistryMyeloperoxidasebiology.proteinHomosteroidsMarine Toxinslipids (amino acids peptides and proteins)medicine.symptomLeukocyte ElastaseNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

Effect of legume grains as a source of dietary protein on the quality of organic lamb meat.

2011

BACKGROUND: This study evaluated the effects on lamb growth, carcass traits and meat quality of replacing conventional soybean meal in the diet with alternative legume grains. RESULTS: Twenty-eight male lambs of Comisana breed weighing 16.9 ± 2.7 kg at weaning (66 ± 6 days old) were assigned to one of four diets. Until slaughter at 129 ± 6 days of age, each group received ad libitum pelleted alfalfa hay and concentrates differing in the source of protein: chickpea, faba bean, pea or soybean meal. Lambs fed chickpea showed higher dry matter and protein intakes from concentrate than those fed soybean. Lambs' growth, carcass weight and net dressing percentage did not vary by protein source, al…

MaleSettore AGR/19 - Zootecnica SpecialeMeatAnimal feedanimal diseasesLinoleic acidConjugated linoleic acidSoybean mealpeaSensationBiologyWeight Gainfaba beansoybean mealchemistry.chemical_compoundchickpeamedicineFood QualityAnimalsHumansDry matterFood scienceLegumeSheep DomesticAdiposityNutrition and Dieteticsintramuscular fatty acid compositionlamb meatdigestive oral and skin physiologySeed Storage ProteinsPeasfood and beveragesFabaceaeAnimal FeedBreedCicerSettore AGR/02 - Agronomia E Coltivazioni ErbaceeVicia fabaTendernesschemistryItalySeedsFatty Acids UnsaturatedFood Organicmedicine.symptomAgronomy and Crop ScienceFood ScienceBiotechnologyAnimals Inbred StrainsJournal of the science of food and agriculture
researchProduct

Presynaptic effects of anandamide and WIN55,212-2 on glutamatergic nerve endings isolated from rat hippocampus

2006

We examined the effects of the endocannabinoide-anandamide (AEA), the synthetic cannabinoid, WIN55,212-2, and the active phorbol ester, 4-beta-phorbol 12-myristate 13-acetate (4-beta-PMA), on the release of [(3)H]d-Aspartate ([(3)H]d-ASP) from rat hippocampal synaptosomes. Release was evoked with three different stimuli: (1) KCl-induced membrane depolarization, which activates voltage-dependent Ca(2+) channels and causes limited neurotransmitter exocytosis, presumably from ready-releasable vesicles docked in the active zone; (2) exposure to the Ca(2+) ionophore-A23187, which causes more extensive transmitter release, presumably from intracellular reserve vesicles; and (3) K(+) channel block…

MaleSettore BIO/14 - FARMACOLOGIAPolyunsaturated AlkamideshippocampusMorpholinesmedicine.medical_treatmentPresynaptic TerminalsArachidonic AcidsNaphthalenesExocytosisCellular and Molecular Neurosciencechemistry.chemical_compoundGlutamatesglutamate releasemedicineAnimalsanandamideActive zoneRats WistarNeurotransmitterCannabinoidCalcimycinProtein kinase CSynaptosomeArachidonic AcidChemistrysynaptosomesDepolarizationCell BiologyAnandamideHippocampal synaptosomeCalcium Channel BlockersBenzoxazinesRatsBiochemistryBiophysicsTetradecanoylphorbol AcetateCannabinoidCapsaicinEndocannabinoidsNeurochemistry International
researchProduct

The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population.

2006

Abstract The genetic etiology of familial hypobetalipoproteinemia (FHBL) is unclear in the majority of cases. Mutations in apolipoprotein B (APOB) are the only confirmed causes of FHBL. Recently, loss-of-function mutations of PCSK9 gene have been shown to be associated with the hypocholesterolemia phenotype. Our primary goal was to confirm that mutations in PCSK9 could be another cause of FHBL. Using the sequencing approach, we found that the c.43_44insCTG variation in PCSK9, a common in-frame insertion in both African American and Caucasian populations, is associated with the hypocholesterolemia phenotype in three FHBL families. Then we tested whether this variation could be associated wit…

MaleSettore MED/09 - Medicina InternaApolipoprotein BDNA Mutational Analysismedicine.disease_causePCSK9Hypobetalipoproteinemiaschemistry.chemical_compoundGene Frequencyapolipoprotein BChildGenetics (clinical)Aged 80 and overMutationeducation.field_of_studybiologySerine EndopeptidasesMiddle AgedPedigreefamilial hypobetalipoproteinemiaPhenotypeChild Preschoollipids (amino acids peptides and proteins)FemaleProprotein ConvertasesProprotein Convertase 9Adultmedicine.medical_specialtyAdolescentPopulationMolecular Sequence DataWhite PeopleLDLlipidInternal medicineGeneticsmedicineHumanseducationAllele frequencyAgedhypocholesterolemiaCholesterolPCSK9Cholesterol HDLCholesterol LDLmedicine.diseaseHypocholesterolemiaEndocrinologychemistryMutationbiology.proteinLipoproteinHuman mutation
researchProduct

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

2021

Background The European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (FHSC) global registry provides a platform for the global surveillance of familial hypercholesterolaemia through harmonisation and pooling of multinational data. In this study, we aimed to characterise the adult population with heterozygous familial hypercholesterolaemia and described how it is detected and managed globally. Methods Using FHSC global registry data, we did a cross-sectional assessment of adults (aged 18 years or older) with a clinical or genetic diagnosis of probable or definite heterozygous familial hypercholesterolaemia at the time they were entered into the registries. Dat…

MaleSettore MED/09 - Medicina InternaArterial diseaseCross-sectional studyAdult populationCoronary DiseaseDiseaseGlobal HealthMedical and Health SciencesDoenças Cardio e Cérebro-vascularesAnticholesteremic AgentMonoclonalPrevalenceRegistriesFamilial HypercholesterolemiaHumanizedStroke11 Medical and Health SciencesLS2_9Studies CollaborationAnticholesteremic AgentsGeneral MedicineHeart Disease Risk FactorMiddle AgedFHSC global registry dataEuropeTreatment OutcomeLower prevalenceGuidancelipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Familial hypercholesterolaemiaLife Sciences & BiomedicineHumanAdultmedicine.medical_specialtyCombination therapyFHSC global registry heterozygous familial hypercholesterolaemiaCardiovascular risk factorsAntibodies Monoclonal HumanizedInsightsAntibodiesNOHyperlipoproteinemia Type IIClinicianMedicine General & InternalInternal medicineGeneral & Internal MedicineHealth SciencesmedicineHumansEAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)Cross-Sectional StudieScience & TechnologyGlobal Perspectivebusiness.industryCholesterol LDLmedicine.diseaseCross-Sectional StudiesHeart Disease Risk FactorsHydroxymethylglutaryl-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase Inhibitorsbusiness
researchProduct